Clinical Trials
18 trialsNCT04800822 2026-06-04
PF-07284892 in Participants With Advanced Solid Tumors
Pfizer
Phase 1 Terminated
NCT02467582 2025-05-16
Adjuvant Aspirin Treatment for Colon Cancer Patients
Swiss Cancer Institute
Phase 3 Terminated
NCT04899349 2024-10-09
EPIK-B4
Novartis
Phase 2 Terminated
NCT05764915 2024-08-01
A Phase I Study of RGT-264 in Subjects With Advanced Solid Tumors
Regor Pharmaceuticals Inc.
Phase 1 Terminated
NCT02718300 2024-05-01
A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis
Incyte Corporation
Phase 2 Terminated
NCT04586335 2024-03-21
Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.
Haihe Biopharma Co., Ltd.
Phase 1 Terminated
NCT02204982 2023-09-28
DYNAMO + R
SecuraBio
Phase 3 Terminated
NCT03565991 2023-09-25
Javelin BRCA/ATM: Avelumab Plus Talazoparib in Patients With BRCA or ATM Mutant Solid Tumors
Pfizer
Phase 2 Terminated
NCT02961283 2023-05-09
Study of ASN003 in Subjects With Advanced Solid Tumors
Asana BioSciences
Phase 1 Terminated
NCT02292225 2023-02-27
Duvelisib With Obinutuzumab in Patients With CLL/SLL Previously Treated With a BTKi (SYNCHRONY)
SecuraBio
Phase 1 Terminated
NCT03386162 2022-11-28
SAFIR-PI3K
UNICANCER
Phase 2 Terminated
NCT04330625 2022-11-08
Glucagon Receptor Inhibition to Enable Breast Cancer Patients to Benefit From PI3K Inhibitor Therapy (REMD-477)
Duke University
Phase 1 Terminated
NCT01602315 2020-12-29
A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Novartis
Phase 1/2 Terminated
NCT01942993 2020-09-30
The Effects of Treatment With Vemurafenib on the Immune System in Advanced Melanoma
Icahn School of Medicine at Mount Sinai
Phase 2 Terminated
NCT03074825 2019-07-24
Study of Chiauranib in Relapsed/Refractory Non-Hodgkin's Lymphoma
Chipscreen Biosciences, Ltd.
Phase 1 Terminated
NCT01633060 2019-01-30
BELLE-3
Novartis
Phase 3 Terminated
NCT02644122 2018-07-11
SF1126 in Recurrent or Progressive SCCHN and Mutations in PIK3CA Gene and/or PI-3 Kinase Pathway Genes
University of California, San Diego
Phase 2 Terminated
NCT00996892 2016-12-30
Safety, Tolerability and Pharmacokinetics of Cobimetinib in Combination With Pictilisib in Patients With Locally Advanced or Metastatic Solid Tumors
Genentech, Inc.
Phase 1 Terminated